Results 181 to 190 of about 184,459 (252)

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Diagnostic accuracy of interferon-gamma release assay and mucosal-associated invariant T cells in spinal tuberculosis. [PDF]

Sci Rep
Mekariya K, Ayutthaya PSN, Naowanirut A, Wongsa A, Tassaneetrithep B, Tantibhedhyangkul W, Ngamskulrungroj P, Muangsomboon S, Cheiwvit P, Wilartratsami S, Luksanapruksa P, Danchaivijitr N, Boonchai K, Rattanatanasarn A, Ruangchainikom M.   +14 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Quinovic Acid Enhances the Cytotoxicity of KHYG-1 Cells by Modulating the Ras/MAPK Signalling Pathway and Interferon-Gamma Expression. [PDF]

J Cell Mol Med
Hsieh MJ, Lin JT, Chuang YC, Ho HY, Lo YS, Lin CC, Chen MK.   +6 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Clinical course and outcomes of patients with anti-interferon-gamma autoantibody-associated adult-onset immunodeficiency: an observational cohort study. [PDF]

Ann Med
Angkasekwinai N, Wongsawat E, Vorasan N.
europepmc   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Interferon gamma rebalances immunopathological signatures in chronic granulomatous disease through metabolic rewiring. [PDF]

Blood Adv
Bruno M, Kröger C, Ferreira AV, Zhang B, Röring RJ, Liu R, van der Made CI, van Rhijn N, Groh L, Klück V, Janssen NAF, Li W, Rosati D, Alaswad A, Tercan H, Saiz J, Gonzalez-Riano C, van Uelft M, Gaal OI, Müller S, Ferreira HJ, Warnat-Herresthal S, Becker M, Holsten L, Kraut M, Schulte-Schrepping J, Bonaguro L, Händler K, Cunha C, Schmolz M, Schultze JL, Joosten LAB, Barbas C, Netea MG, Li Y, Aschenbrenner AC, Carvalho A, van de Veerdonk FL.   +37 more
europepmc   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Alternative Splicing as a Modulator of the Interferon-Gamma Pathway. [PDF]

Cancers (Basel)
Suri P, Badalov A, Ruggiu M.
europepmc   +1 more source